139 related articles for article (PubMed ID: 35759882)
21. Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
Ferrari SM; La Motta C; Sartini S; Baldini E; Materazzi G; Politti U; Ruffilli I; Ulisse S; Miccoli P; Antonelli A; Fallahi P
Mini Rev Med Chem; 2016; 16(2):86-93. PubMed ID: 26471970
[TBL] [Abstract][Full Text] [Related]
22. Discovery of N-Phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine Derivatives as Potent Mnk2 Inhibitors: Design, Synthesis, SAR Analysis, and Evaluation of in vitro Anti-leukaemic Activity.
Abdelaziz AM; Diab S; Islam S; Basnet SKC; Noll B; Li P; Mekonnen LB; Lu J; Albrecht H; Milne RW; Gerber C; Yu M; Wang S
Med Chem; 2019; 15(6):602-623. PubMed ID: 30569866
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis and biological evaluation of pyrazolo[3,4-
Wu X; Dai M; Cui R; Wang Y; Li C; Peng X; Zhao J; Wang B; Dai Y; Feng D; Yang T; Jiang H; Geng M; Ai J; Zheng M; Liu H
Acta Pharm Sin B; 2021 Mar; 11(3):781-794. PubMed ID: 33777682
[TBL] [Abstract][Full Text] [Related]
24. A systematic approach to therapeutic target selection in oesophago-gastric cancer.
Paterson AL; Shannon NB; Lao-Sirieix P; Ong CA; Peters CJ; O'Donovan M; Fitzgerald RC
Gut; 2013 Oct; 62(10):1415-24. PubMed ID: 22773546
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts.
Ji F; Liu X; Wu Y; Fang X; Huang G
Drug Des Devel Ther; 2015; 9():5697-704. PubMed ID: 26543351
[TBL] [Abstract][Full Text] [Related]
26. Tyrosine kinase inhibition effects of novel Pyrazolo[1,5-a]pyrimidines and Pyrido[2,3-d]pyrimidines ligand: Synthesis, biological screening and molecular modeling studies.
El Sayed MT; Hussein HAR; Elebiary NM; Hassan GS; Elmessery SM; Elsheakh AR; Nayel M; Abdel-Aziz HA
Bioorg Chem; 2018 Aug; 78():312-323. PubMed ID: 29625271
[TBL] [Abstract][Full Text] [Related]
27. Discovery of 7H-pyrrolo[2,3-d]pyridine derivatives as potent FAK inhibitors: Design, synthesis, biological evaluation and molecular docking study.
Wang R; Zhao X; Yu S; Chen Y; Cui H; Wu T; Hao C; Zhao D; Cheng M
Bioorg Chem; 2020 Sep; 102():104092. PubMed ID: 32707280
[TBL] [Abstract][Full Text] [Related]
28. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
Bakr RB; Mehany ABM; Abdellatif KRA
Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
[TBL] [Abstract][Full Text] [Related]
29. Pyrrolo[2,3-b]pyridine-3-one derivatives as novel fibroblast growth factor receptor 4 inhibitors for the treatment of hepatocellular carcinoma.
Jin Q; Zhang D; Gao M; Jiang C; Zhang J
Bioorg Med Chem; 2021 Jan; 29():115862. PubMed ID: 33218898
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis, and biological evaluation of 2,6,7-substituted pyrrolo[2,3-d]pyrimidines as cyclin dependent kinase inhibitor in pancreatic cancer cells.
Shi X; Quan Y; Wang Y; Wang Y; Li Y
Bioorg Med Chem Lett; 2021 Feb; 33():127725. PubMed ID: 33316409
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and biological evaluation of 6-(pyrimidin-4-yl)-1H-pyrazolo[4,3-b]pyridine derivatives as novel dual FLT3/CDK4 inhibitors.
Li X; Yang T; Hu M; Yang Y; Tang M; Deng D; Liu K; Fu S; Tan Y; Wang H; Chen Y; Zhang C; Guo Y; Peng B; Si W; Yang Z; Chen L
Bioorg Chem; 2022 Apr; 121():105669. PubMed ID: 35180490
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and biological evaluation of novel 1-substituted 3-(3-phenoxyprop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors.
Zheng N; Hao Q; Lin K; Pan J; Li Y; Zhou W
Bioorg Med Chem Lett; 2019 Jan; 29(2):225-229. PubMed ID: 30522954
[TBL] [Abstract][Full Text] [Related]
33. Discovery of CAPE derivatives as dual EGFR and CSK inhibitors with anticancer activity in a murine model of hepatocellular carcinoma.
Liu X; Du Q; Tian C; Tang M; Jiang Y; Wang Y; Cao Y; Wang Z; Wang Z; Yang J; Li Y; Jiao X; Xie P
Bioorg Chem; 2021 Feb; 107():104536. PubMed ID: 33342565
[TBL] [Abstract][Full Text] [Related]
34. Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo.
Yang LL; Li GB; Ma S; Zou C; Zhou S; Sun QZ; Cheng C; Chen X; Wang LJ; Feng S; Li LL; Yang SY
J Med Chem; 2013 Feb; 56(4):1641-55. PubMed ID: 23362959
[TBL] [Abstract][Full Text] [Related]
35. Identification of new pyrrolo[2,3-d]pyrimidines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, biological evaluation and molecular modeling.
Adel M; Serya RAT; Lasheen DS; Abouzid KAM
Bioorg Chem; 2018 Dec; 81():612-629. PubMed ID: 30248512
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and biological activity of N(4)-phenylsubstituted-6-(2,4-dichloro phenylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic and antitumor agents.
Gangjee A; Kurup S; Ihnat MA; Thorpe JE; Shenoy SS
Bioorg Med Chem; 2010 May; 18(10):3575-87. PubMed ID: 20403700
[TBL] [Abstract][Full Text] [Related]
37. Targeting kinases with anilinopyrimidines: discovery of N-phenyl-N'-[4-(pyrimidin-4-ylamino)phenyl]urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily.
Gandin V; Ferrarese A; Dalla Via M; Marzano C; Chilin A; Marzaro G
Sci Rep; 2015 Nov; 5():16750. PubMed ID: 26568452
[TBL] [Abstract][Full Text] [Related]
38. Novel thiazole amine class tyrosine kinase inhibitors induce apoptosis in human mast cells expressing D816V KIT mutation.
Jin Y; Ding K; Wang D; Shen M; Pan J
Cancer Lett; 2014 Oct; 353(1):115-23. PubMed ID: 25088577
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and Anti-Proliferative Evaluations of New Heterocyclic Derivatives Using 5,6,8,9-Tetrahydropyrazolo[5,1-b]quinazolin-7(3H)-one Derivatives Derived from Cyclohexa-1,4-dione.
Mahmoud MAA; Alsharif MA; Mohareb RM
Anticancer Agents Med Chem; 2021; 21(4):468-486. PubMed ID: 32445457
[TBL] [Abstract][Full Text] [Related]
40. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W
Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
